The monoclonal antibody RBD.01 recognizes SARS-CoV-2 receptor binding domain (RBD) of Spike protein.
SARS-CoV-2 Spike protein is a structural transmembrane glycoprotein comprised of two subunits (S1 and S2), size of 180–200 kDa. It protrudes from the surface of the SARS-CoV-2 virion and is essential for binding to the host cell via host ACE-2 receptor. Spike protein is a main target for neutralizing antibodies and vaccines. Our anti-Spike antibody clone RBD.01 was validated in ELISA (on recombinant Spike and RBD proteins), FACS (on SARS-CoV-2 infected 293T-ACE2 cells) and WB (on recombinant RBD protein), as described in Pribanić Matešić et al. Viruses 2022, 14(2), 443.
Clone RBD.01 binds to Spike corresponding to variants B.1.1.7, B.1.351 and B.1.617.2 (validated in FACS on infected Vero cells) and to RBD corresponding to Omicron variant (validated in ELISA on recombinant RBD protein).